As evidenced from the cardiovascular outcome trials, SGLT2 inhibitors have been shown to lower the incidence of atherosclerotic disease, including myocardial infarction and non-fatal stroke, and decrease heart failure-related sequelae and cardiovascular death. Here, SLC5A2 is linked to stroke disorder.